Get started
Award

CA180791

Funded outputs count: 15
Funder award ID: CA180791
OpenAlex ID: G5020521663
Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia
2020 · Koichi Oshima, Junfei Zhao, et al. · Nature Cancer · 67
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
2019 · Tait D. Shanafelt, Xin V. Wang, et al. · New England Journal of Medicine · 750
PDF
Faculty Opinions recommendation of PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.
2019 · Jan Starý, Barbora Vakrmanova · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
PDF
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease
2018 · Mark R. Litzow, Xin V. Wang, et al. · American Journal of Hematology · 27
PDF
Does biomarker information impact breast cancer patients’ preferences and physician recommendation for adjuvant chemotherapy?
2017 · Ann H. Partridge, Karen Sepucha, et al. · Breast Cancer Research and Treatment · 5
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E2607)
2017 · Kevin Kalinsky, Sandra Lee, et al. · Cancer · 128
PDF
Survival benefit needed to undergo chemotherapy: Patient and physician preferences
2017 · Ines Vaz‐Luis, Anne O'Neill, et al. · Cancer · 29
PDF
High Frequency and Poor Outcome of Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia in Adults
2017 · Kathryn G. Roberts, Zhaohui Gu, et al. · Journal of Clinical Oncology · 453
Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008
2016 · Chezi Ganzel, Judith Manola, et al. · Journal of Clinical Oncology · 138
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive‐stage small cell lung cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E1508)
2016 · Chandra P. Belani, Suzanne E. Dahlberg, et al. · Cancer · 68
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
2016 · Marlise R. Luskin, Ju-Whei Lee, et al. · Blood · 124
A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG‐ACRIN cancer research group (E1908)
2015 · Clive S. Zent, Xin Victoria Wang, et al. · American Journal of Hematology · 15
Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia
2015 · R B Walter, M Othus, et al. · Leukemia · 54
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997
2015 · David M. Lucas, Amy S. Ruppert, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 9
Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program
2015 · Sun-Mi Park, Mithat Gönen, et al. · Journal of Clinical Investigation · 110
Year
Topic